Patents by Inventor Francis J Carr

Francis J Carr has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7524502
    Abstract: The invention relates to the modification of antibodies reactive to human tumor necrosis factor alpha (TNF alpha) to result in anti-TNF alpha antibodies that are substantially non-immunogenic or less immunogenic than any non-modified parental antibody when used in vivo. The invention relates also to peptide molecules comprising T-cell epitopes of the V-regions of the parental antibody which are modified by amino acid alteration in order to reduce or eliminate said T-cell epitopes.
    Type: Grant
    Filed: November 11, 2002
    Date of Patent: April 28, 2009
    Assignee: Merck Patent GmbH
    Inventors: Koen Hellendoorn, Matthew Baker, Francis J. Carr
  • Publication number: 20090092546
    Abstract: The present invention relates generally to carrier molecules derived from one animal or avian species or strains and which are substantially non-immunogenic when exposed to an immune system from a species or strain of another animal or avian creature. More particularly, the present invention provides deimmunized immunointeractive molecules and even more particular deimmunized antibodies for use in diagnostic and therapeutic applications.
    Type: Application
    Filed: September 2, 2008
    Publication date: April 9, 2009
    Applicant: Agen Biomedical Limited
    Inventors: Francis J. Carr, Anita A. Hamilton
  • Patent number: 7514078
    Abstract: Modified antibodies, or antigen-binding fragments thereof, to the extracellular domain of human prostate specific membrane antigen (PSMA) are provided. The modified anti-PSMA antibodies, or antigen-binding fragments thereof, have been rendered less immunogenic compared to their unmodified counterparts to a given species, e.g., a human. Pharmaceutical compositions including the aforesaid antibodies, nucleic acids, recombinant expression vectors and host cells for making such antibodies and fragments are also disclosed. Methods of using the antibodies of the invention to detect human PSMA, or to ablate or kill a PSMA-expressing cell, e.g., a PSMA-expressing cancer or prostatic cell, either in vitro or in vivo, are also provided.
    Type: Grant
    Filed: May 30, 2003
    Date of Patent: April 7, 2009
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Neil H. Bander, Francis J. Carr, Anita Hamilton
  • Publication number: 20090043076
    Abstract: The present invention relates a modified human interferon beta (INF?) which is less immunogenic than human INF? (SEQ ID NO: 1) when administered in vivo to a human. The modified human INF? comprises an amino acid residue sequence that differs from SEQ ID NO: 1 by an amino acid residue substitution selected from the group consisting of L57A, L57C, L57D L57E, L57G, L57H, L57K, L57N, L57P, L57Q, L57R, L57S, and L57T and an additional substitution selected from the group consisting of the H140A, H140C, H140G, and H140P.
    Type: Application
    Filed: March 17, 2008
    Publication date: February 12, 2009
    Inventors: Francis J. Carr, Graham Carter, Tim Jones, John Watkins, Matthew Baker
  • Publication number: 20090022738
    Abstract: The present invention provides a cytotoxically active CD3 specific binding construct comprising a first domain specifically binding to human CD3 and an Ig-derived second binding domain. Furthermore, a nucleic acid sequence encoding a CD3 specific binding construct of the invention is provided. Further aspects of the invention are vectors and host cells comprising said nucleic acid sequence, a process for the production of the construct of the invention and composition comprising said construct. The invention also provides the use of said constructs for the preparation of pharmacutical compositions for the treatment of particular diseases, a method for the treatment of particular diseases and a kit comprising the binding construct of the invention.
    Type: Application
    Filed: October 15, 2004
    Publication date: January 22, 2009
    Inventors: Robert Hofmeister, Birgit Kohleisen, Ulla Lenkkeri-Schutz, Christian Itin, Patrick Bauerle, Francis J. Carr, Anita A. Hamilton, Stephen Williams
  • Patent number: 7459143
    Abstract: The present invention relates generally to carrier molecules derived from one animal or avian species or strains and which are substantially non-immunogenic when exposed to an immune system from a species or strain of another animal or avian creature. More particularly, the present invention provides deimmunized immunointeractive molecules and even more particular deimmunized antibodies for use in diagnostic and therapeutic applications.
    Type: Grant
    Filed: May 10, 2006
    Date of Patent: December 2, 2008
    Assignee: Agen Biomedical Ltd.
    Inventors: Francis J. Carr, Anita A. Hamilton
  • Publication number: 20080248529
    Abstract: The present invention provides for modified forms of anti-CD52 antibodies with reduced numbers of potential T-cell epitopes that are expected to display decreased immunogenicity.
    Type: Application
    Filed: October 31, 2007
    Publication date: October 9, 2008
    Inventors: FRANCIS J. CARR, Anita A. Hamilton
  • Patent number: 7430476
    Abstract: This invention relates to a novel approach for identification of T-cell epitopes, that give rise to an immune reaction in a living host. By means of this novel method biological compounds can be generated which have a no or at least a reduced immunogenicity when exposed to the immune system of a given species and compared with the relevant non-modified entity. Thus the invention relates also to novel biological molecules, especially proteins and antibodies, obtained by the method according to the invention.
    Type: Grant
    Filed: February 18, 2002
    Date of Patent: September 30, 2008
    Assignee: Merck Patent GmbH
    Inventors: Francis J. Carr, Graham Carter, Tim Jones, Stephen Williams, Anita Hamilton
  • Publication number: 20080219994
    Abstract: The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer.
    Type: Application
    Filed: January 9, 2008
    Publication date: September 11, 2008
    Inventors: Matthew Baker, Francis J. Carr, Koen Hellendoorn, Jeannick Cizeau, Glen Christopher MacDonald, Joycelyn Entwistle, Denis Georges Bosc, Nicholas Ronald Glover
  • Patent number: 7392141
    Abstract: A method of preparing a modified granulocyte colony stimulating factor (G-CSF) protein having reduced immunogenicity relative to human G-CSF comprises the steps of (i) identifying one or more potential T-cell epitopes within the amino acid sequence of human G-CSF (SEQ ID NO: 1); (ii) designing at least one sequence variant of at least one potential T-cell epitope identified in step (i), wherein the sequence variant eliminates or substantially reduces the MHC class II binding activity of the potential T-cell epitope; (iii) preparing, by recombinant DNA techniques, at least one modified G-CSF protein including a sequence variant designed in step (ii); (iv) evaluating at least one modified G-CSF protein prepared in step (iii) for G-CSF activity and immunogenicity; and (v) selecting a modified G-CSF protein evaluated in step (iv) that has substantially the same therapeutic G-CSF biological activity as, but substantially less immunogenicity than, human G-CSF.
    Type: Grant
    Filed: February 5, 2002
    Date of Patent: June 24, 2008
    Assignee: Merck Patent GmbH
    Inventors: Francis J. Carr, Graham Carter, Tim Jones, Stephen Williams
  • Patent number: 7381795
    Abstract: A modified interferon beta (INF?) is provided, which is less immunogenic than human INF? (SEQ ID NO: 1) when administered to a human in vivo. The modified INF? comprises an amino acid residue sequence that differs from SEQ ID NO: 1 by a substitution at one or more residues of SEQ ID NO: 1. Preferred substitutions are at residues selected from the group consisting of residue 50, 59, 60, 62, 63, 66, 67, 69, 70, 125, 126, 129, 130, 132, 133, and 138. Examples of suitable substitutions include F50A, L57A, I59A, Y60N, M62A, L63A, I66T, F67H, I69A, F70A, Y125A, Y126A, I129A, L130A, Y132S, L133A, Y138H, and Y138A.
    Type: Grant
    Filed: March 15, 2002
    Date of Patent: June 3, 2008
    Assignee: Merck Patent GmbH
    Inventors: Francis J. Carr, Graham Carter, Tim Jones, John Watkins, Matthew Baker
  • Patent number: 7351540
    Abstract: Novel methods for the identification and/or sequencing of proteins are provided. These methods are particularly suited to screening antibody libraries and in preferred embodiments make use of mass spectrometry techniques for direct or indirect sequencing.
    Type: Grant
    Filed: March 17, 2000
    Date of Patent: April 1, 2008
    Assignee: Merck Patent GmbH
    Inventor: Francis J. Carr
  • Patent number: 7339031
    Abstract: The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer.
    Type: Grant
    Filed: March 18, 2005
    Date of Patent: March 4, 2008
    Assignee: Merck Patent GmbH
    Inventors: Matthew Baker, Francis J. Carr, Koen Hellendoorn, Jeannick Cizeau, Glen Christopher MacDonald, Joycelyn Entwistle, Denis Georges Bosc, Nicholas Ronald Glover
  • Patent number: 7264806
    Abstract: The present invention provides for modified forms of anti-CD52 antibodies with reduced numbers of potential T-cell epitopes that are expected to display decreased immunogenicity.
    Type: Grant
    Filed: October 29, 2004
    Date of Patent: September 4, 2007
    Assignee: Biovation Ltd.
    Inventors: Francis J. Carr, Anita A. Hamilton
  • Patent number: 7189830
    Abstract: The invention relates to artificial modified proteins, preferably fusion proteins, having a reduced immunogenicity compared to the parent non-modified molecule when exposed to a species in vivo. The invention relates, above all, to novel immunoglobulin fusion proteins which essentially consist of an immunoglobulin molecule or a fragment thereof covalently fused via its C-terminus to the N-terminus of a biologically active non-immunoglobulin molecule, preferably a polypeptide or protein or a biologically active fragment thereof. In a specific embodiment, the invention relates to fusion proteins consisting of an Fc portion of an antibody which is fused as mentioned to the non-immunological target molecule which elicits biological or pharmacological efficacy. The molecules of the invention have amino acid sequences which are altered in one or more amino acid residue positions but have in principal the same biological activity as compared with the non-altered molecules.
    Type: Grant
    Filed: February 18, 2002
    Date of Patent: March 13, 2007
    Assignee: Merck Patent GmbH
    Inventors: Stephen Gillies, Francis J. Carr, Jones Tim, Graham Carter, Anita Hamilton, Stephen Williams, Marian Hanlon, John Watkins, Matthew Baker, Jeffrey C. Way
  • Patent number: 7132511
    Abstract: The present invention relates to antibodies which are directed to the EGF receptor (HER1) to be administered especially to humans and in particular for therapeutic use in tumors. The antibodies are modified whereby the modification results in a reduced propensity for the antibody to elicit an immune response upon administration to the human subject. The invention in particular relates to the modification of anti-EGFR antibody 425 in its different forms and fragments thereof to result in Mab 425 variants that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo.
    Type: Grant
    Filed: February 18, 2002
    Date of Patent: November 7, 2006
    Assignee: Merck Patent GmbH
    Inventors: Francis J. Carr, Graham Carter, Tim Jones, Stephen Williams, Anita Hamilton
  • Patent number: 7087724
    Abstract: The present invention relates generally to carrier molecules derived from one animal or avian species or strains and which are substantially non-immunogenic when exposed to an immune system from a species or strain of another animal or avian creature. More particularly, the present invention provides deimmunized immunointeractive molecules and even more particular deimmunized antibodies for use in diagnostic and therapeutic applications.
    Type: Grant
    Filed: June 26, 2002
    Date of Patent: August 8, 2006
    Assignee: Agen Biomedical Ltd
    Inventors: Francis J. Carr, Anita A. Hamilton
  • Patent number: 7045605
    Abstract: Modified antibodies, or antigen-binding fragments thereof, to the extracellular domain of human prostate specific membrane antigen (PSMA) are provided. The modified anti-PSMA antibodies, or antigen-binding fragments thereof, have been rendered less immunogenic compared to their unmodified counterparts to a given species, e.g., a human. Pharmaceutical compositions including the aforesaid antibodies, nucleic acids, recombinant expression vectors and host cells for making such antibodies and fragments are also disclosed. Methods of using the antibodies of the invention to detect human PSMA, or to ablate or kill a PSMA-expressing cell, e.g., a PSMA-expressing cancer or prostatic cell, either in vitro or in vivo, are also provided.
    Type: Grant
    Filed: May 30, 2002
    Date of Patent: May 16, 2006
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Neil Bander, Francis J. Carr, Anita Hamilton
  • Patent number: 6974699
    Abstract: A method of releasing an agent for example, a chemotherapeutic, under predetermined conditions by protecting the agent within a lipid structure such as a liposome, causing lipase activity to be constituted by combining two or more components, e.g., recombinant N- or C-terminal Clostridium perfringens alpha-toxin fragments, one of these components being conjugated to a targeting molecule e.g., an antibody which binds to a target such as a tumor antigen. The lipid structure is then exposed to the constituted lipase activity such as to release the agent. Also disclosed are materials and kits for use in the method.
    Type: Grant
    Filed: November 21, 2001
    Date of Patent: December 13, 2005
    Assignee: Biovation Limited
    Inventors: Richard W Titball, Francis J Carr
  • Publication number: 20040260069
    Abstract: The invention relates to the modification of antibodies reactive to human tumor necrosis factor alpha (TNF alpha) to result in anti-TNF alpha antibodies that are substantially non-immunogenic or less immunogenic than any non-modified parental antibody when used in vivo. The invention relates also to peptide molecules comprising T-cell epitopes of the V-regions of the parental antibody which are modified by amino acid alteration in order to reduce or eliminate said T-cell epitopes.
    Type: Application
    Filed: May 10, 2004
    Publication date: December 23, 2004
    Inventors: Koen Hellendoorn, Matthew Baker, Francis J. Carr